The phase 1 study is intended to characterize the safety, tolerability, and feasibility of intravesical administration of UGN-501.
|Slideshows|December 13, 2019
Top 5 bladder cancer articles of 2019
The BCG shortage, overuse of cystoscopy, and hematuria evaluation approaches are among the topics of the most-read Urology Times articles from 2019 on bladder cancer.
Advertisement
Advertisement
Related to this article
Paras H. Shah, MD, recaps data on emerging agents in high-risk NMIBC from the 2026 AUA North Central Section Meeting.
Five-year follow-up data show durable responses with UGN-101 in patients with low-grade upper tract urothelial carcinoma who achieved an initial complete response.
A recap of the FDA submissions and regulatory decisions in urology from October 2026.
Topline results are expected in November 2026 ahead of a planned sBLA submission.
A comprehensive guide to the top data in genitourinary oncology presented at ESMO 2026.
In a POTOMAC subgroup analysis, durvalumab plus BCG reduced the risk of high-risk recurrence or death by 44% vs BCG alone in patients with papillary-only, BCG-naive NMIBC.
Andrea Necchi, MD, discusses how results from the CA017-078 trials compares with other perioperative immunotherapy trials in muscle-invasive bladder cancer.
Advertisement
Advertisement
Trending on Urology Times
1
ESMO 2026 On Location - Why pCR is not the whole story in cisplatin-ineligible MIBC
2
UGN-501 enters phase 1 testing for recurrent non–muscle invasive bladder cancer
3
2026 AUA North Central Section Meeting: Updates in high-risk NMIBC
4
UGN-101 shows durable responses in low-grade upper tract urothelial carcinoma
5